Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hengrui Medicine Licenses Cancer Drug to Incyte in $795 Million Deal

publication date: Sep 2, 2015
Jiangsu Hengrui Medicine out-licensed global rights (ex-China) for its clinical-stage anti-PD-1 monoclonal antibody to Incyte in a deal potentially worth $795 million. Incyte paid $25 million upfront. Hengrui's SHR-1210 is expected to start a China Phase II trial in patients with solid tumor cancers in the next few months. Hengrui will retain rights in mainland China, Hong Kong, Macau and Taiwan. Incyte, headquartered in Delaware, described the relationship as a combination of licensing and collaboration. More details....

Stock Symbols: (SHA: 600276)  (NSDQ: INCY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital